Your session is about to expire
← Back to Search
Bortezomib following nonmyeloablative allogeneic transplant for Multiple Myeloma
Study Summary
This trial is testing whether a common cancer drug called Bortezomib can help people with myeloma who are getting a stem cell transplant. Myeloma is hard to treat and often comes back after treatment, so the hope is that this might help keep it in check better.
- Multiple Myeloma
- Cancer
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Bortezomib post-transplantation
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants are being accepted into this experimental study?
"Unfortunately, this medical trial is no longer open for patient recruitment. It was initially published on November 1st 2014 and last edited on August 22nd 2022. For those seeking other trials, 813 studies concerning multiple myeloma are actively recruiting participants as well as 142 clinical trials involving Bortezomib after a nonmyeloablative allogeneic transplantation."
Is this trial accepting new participants?
"Unfortunately, the clinical trial listed on clinicialtrials.gov is no longer actively seeking participants; it was initially posted during November 2014 and last updated in August 2022. However, many other trials are recruiting patients right now - 955 to be exact."
Is this research endeavor open to participants over the age of two decades?
"This medical study is limited to individuals aged 18-65 years old. For those younger or older, there are 54 and 928 studies respectively that may be more appropriate for their age groups."
Has the administration given their sanction to Bortezomib following nonmyeloablative allogeneic transplant?
"Bortezomib following nonmyeloablative allogeneic transplant is assumed to have a safety rating of 2 since this clinical trial is only in Phase 2, meaning there are data points that suggest it can be relatively safe but no efficacy has been established yet."
Is there any opportunity to participate in this investigation?
"To be enumerated in this trial, patients must have a diagnosis of multiple myeloma as well as meet the age requirement of 18-65. At present, there are 40 places available."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger